New Market - June 8, 2015
AZ’s Interest in Immuno-oncology Grows
AstraZeneca and Medimmune, AstraZeneca PLC’s global biologics research and development unit, gave a presentation on the company’s pipeline in the area of immuno-oncology at the recent American Society of Clinical Oncology meeting. Immuno-oncology involves programming or stimulating the body’s own immune system to attack cancer cells, according to BioSpace.com. The companies reported on a number of pipeline […]
New Market - June 1, 2015
Isofol Drug Receives US Patent
The use and pharmaceutical composition of Isofol Medical AB’s [6R]-methylene-tetrahydrofolate (Modufolin®), to reduce toxicity resulting from multi-targeting antifolate chemotherapy, has received a patent from the U.S. Patent and Trademark Office. Modufolin® is a folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. Isofol provided evidence demonstrating the […]
New Market - April 3, 2015
AZ Drug on Swedish Market
AstraZeneca Pharmaceutical’s naloxegol or Moventig, is now available on the Swedish market, the first country in Europe since approval for the European market was granted in 2014. In mid- September 2014, naloxgel was approved for use in the U.S. under the name Movantik. It was launched on the US market this week. Naloxegol is intended […]
New Market - January 27, 2015
Novo to Market Saxenda in U.S.
Novo Nordisk plans to put 500 U.S. sales reps, or about one-sixth of that country’s sales force, to work marketing its newly-approved weight-loss drug Saxenda, a reformulated version of diabetes drug Victoza (liraglutide). In an interview with the Financial Times, Novo Chief Science Officer Mads Krogsgaard Thomsen said his company is looking to generate at […]
New Market - November 19, 2014
Recognition for Nordic Biomarker
Sweden’s Nordic Biomarker is having a week to remember. First it earned the spin-off company of the year award at Umeågalan, and then discovered it made Deloitte’s list of the fastest growing tech companies in Sweden. Nordic Biomarker manufactures reagents for diagnostic tests, which are used to rule out if a patient has had a […]
New Market - November 3, 2014
FDA approves AstraZeneca’s XIGDUO
The US Food and Drug Administration has approved AstraZeneca’s once-daily XIGDUO XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. XIGDUO XR is the first and only once-daily combination tablet of an SGLT2 inhibitor and metformin HCl extended-release to be approved in the United States. XIGDUO XR is indicated […]
